What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review, RCT).

September 10, 2025MedicineOpen Access

Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors?

View Full Paper

Ask AI

Bookmark

Authors

SZShengyu ZhuQuantum Technologies (Sweden)JLJianjiang LiuXidian University XCXialin ChenChina Pharmaceutical University

Discussion

Member takes

Overview

Meta-analysis shows no survival difference between anti-PD-1 and anti-PD-L1 therapies in small-cell lung cancer, suggesting safety advantages to anti-PD-L1.

Key Points

Both anti-PD-1 and anti-PD-L1 therapies yield comparable results in overall survival and progression-free survival.
The analysis of 3339 patients revealed 6-month overall survival rates of 86.6% for anti-PD-1 and 85.5% for anti-PD-L1, indicating similar effectiveness.
A systematic review and meta-analysis of phase III randomized controlled trials was conducted to evaluate these therapies' efficacy.
Both treatment options are equally effective, but anti-PD-L1 appears to have a lower incidence of severe adverse events.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68c1955c9b7b07f3a06193a7 https://doi.org/10.1097/md.0000000000044383

View Full Paper

Ask AI

Bookmark

September 10, 2025MedicineOpen Access

Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors?

View Full Paper

Ask AI

Bookmark

Authors

SZShengyu ZhuQuantum Technologies (Sweden)JLJianjiang LiuXidian University XCXialin ChenChina Pharmaceutical University

Discussion

Member takes

Overview

Meta-analysis shows no survival difference between anti-PD-1 and anti-PD-L1 therapies in small-cell lung cancer, suggesting safety advantages to anti-PD-L1.

Key Points

Both anti-PD-1 and anti-PD-L1 therapies yield comparable results in overall survival and progression-free survival.
The analysis of 3339 patients revealed 6-month overall survival rates of 86.6% for anti-PD-1 and 85.5% for anti-PD-L1, indicating similar effectiveness.
A systematic review and meta-analysis of phase III randomized controlled trials was conducted to evaluate these therapies' efficacy.
Both treatment options are equally effective, but anti-PD-L1 appears to have a lower incidence of severe adverse events.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68c1955c9b7b07f3a06193a7 https://doi.org/10.1097/md.0000000000044383

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark